Patents by Inventor Goran Bauren
Goran Bauren has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11136359Abstract: The invention discloses a polypeptide with improved alkaline stability, which polypeptide comprises a mutant of a B or C domain of Staphylococcus Protein A (SpA), as specified by SEQ ID NO 1 or SEQ ID NO 2, or of Protein Z, as specified by SEQ ID NO 3, wherein at least the glutamine residue at position 9 has been mutated to an amino acid other than asparagine. The invention also discloses multimers of said polypeptide, as well as separation matrices comprising the multimers or polypeptides.Type: GrantFiled: February 20, 2018Date of Patent: October 5, 2021Assignee: Cytiva BioProcess R&D ABInventors: Gustav Rodrigo, Mats Ander, Tomas Bjorkman, Goran Bauren
-
Patent number: 10308690Abstract: The invention discloses a polypeptide with improved alkaline stability, which polypeptide comprises a mutant of a B or C domain of Staphylococcus Protein A (SpA), as specified by SEQ ID NO 1 or SEQ ID NO 2, or of Protein Z, as specified by SEQ ID NO 3, comprising at least the mutation wherein the glutamine residue at position 9 has been mutated to a tryptophan, leucine, glutamic acid, valine or lysine. The invention also discloses multimers of the polypeptide, as well as separation matrices comprising the multimers or polypeptides.Type: GrantFiled: December 7, 2015Date of Patent: June 4, 2019Assignee: GE HEALTHCARE BIOPROCESS R&D ABInventors: Gustav Rodrigo, Mats Ander, Göran Baurén, Tomas Björkman
-
Patent number: 10189891Abstract: The invention discloses an immunoglobulin-binding protein comprising one or more mutated immunoglobulin-binding domains (monomers) of staphylococcal Protein A (E, D, A, B, C) or protein Z or a functional variant thereof, wherein in at least one of the one or more mutated monomers, the asparagine or histidine at the position corresponding to H18 of the B domain of Protein A or of Protein Z has been deleted or substituted with a first amino acid residue which is not proline or asparagine and wherein, if the amino acid residue at position 57 is proline and the amino acid residue at position 28 is asparagine, then the amino acid residue at the position corresponding to H18 of the B domain of protein A or of protein Z is not serine, threonine or lysine.Type: GrantFiled: March 26, 2013Date of Patent: January 29, 2019Assignee: GE Healthcare BioProcess R&D ABInventors: Mats Ander, Goran Bauren, Tomas Bjorkman, Per-Mikael Aberg, Gustav Rodrigo
-
Patent number: 10112980Abstract: The invention discloses a polypeptide with improved alkaline stability, which polypeptide comprises a mutant of a B or C domain of Staphylococcus Protein A (SpA), as specified by SEQ ID NO 1 or SEQ ID NO 2, or of Protein Z, as specified by SEQ ID NO 3, wherein at least the glutamic acid residue at position 15 has been mutated to an amino acid other than asparagine. The invention also discloses multimers of said polypeptide, as well as separation matrices comprising the multimers or polypeptides.Type: GrantFiled: May 18, 2017Date of Patent: October 30, 2018Assignee: GE HEALTHCARE BIOPROCESS R&D ABInventors: Mats Ander, Goran Bauren, Tomas Bjorkman, Gustav Rodrigo
-
Publication number: 20180244729Abstract: The invention discloses a polypeptide with improved alkaline stability, which polypeptide comprises a mutant of a B or C domain of Staphylococcus Protein A (SpA), as specified by SEQ ID NO 1 or SEQ ID NO 2, or of Protein Z, as specified by SEQ ID NO 3, wherein at least the glutamine residue at position 9 has been mutated to an amino acid other than asparagine. The invention also discloses multimers of said polypeptide, as well as separation matrices comprising the multimers or polypeptides.Type: ApplicationFiled: February 20, 2018Publication date: August 30, 2018Applicant: GE Healthcare BioProcess R&D ABInventors: Gustav Rodrigo, Mats Ander, Tomas BJORKMAN, Goran Bauren
-
Patent number: 9896486Abstract: A polypeptide with improved alkaline stability, which polypeptide comprises a mutant of a B or C domain of Staphylococcus Protein A, as specified by SEQ ID NO 1 or SEQ ID NO 2, or of Protein Z, as specified by SEQ ID NO 3, wherein at least the glutamine residue at position 9 has been mutated to an amino acid other than asparagine. The invention also discloses multimers of said polypeptide, as well as separation matrices comprising the multimers or polypeptides.Type: GrantFiled: July 8, 2014Date of Patent: February 20, 2018Assignee: GE Healthcare BioProcess R&D ABInventors: Gustav Rodrigo, Mats Ander, Tomas Bjorkman, Goran Bauren
-
Publication number: 20170320922Abstract: The invention discloses a polypeptide with improved alkaline stability, which polypeptide comprises a mutant of a B or C domain of Staphylococcus Protein A (SpA), as specified by SEQ ID NO 1 or SEQ ID NO 2, or of Protein Z, as specified by SEQ ID NO 3, wherein at least the glutamic acid residue at position 15 has been mutated to an amino acid other than asparagine. The invention also discloses multimers of said polypeptide, as well as separation matrices comprising the multimers or polypeptides.Type: ApplicationFiled: May 18, 2017Publication date: November 9, 2017Applicant: GE HEALTHCARE BIO-SCIENCES ABInventors: Mats ANDER, Goran BAUREN, Tomas BJORKMAN, Gustav RODRIGO
-
Patent number: 9663558Abstract: A polypeptide with improved alkaline stability, which polypeptide comprises a mutant of a B or C domain of Staphylococcus Protein A, as specified by SEQ ID NO 1 or SEQ ID NO 2, or of Protein Z, as specified by SEQ ID NO 3, wherein at least the glutamine residue at position 15 has been mutated to an amino acid other than asparagine. The invention also discloses multimers of the polypeptide, as well as separation matrices comprising the multimers or polypeptides.Type: GrantFiled: July 10, 2014Date of Patent: May 30, 2017Assignee: GE Healthcare Bio-Sciences ABInventors: Mats Ander, Goran Bauren, Tomas Bjorkman, Gustav Rodrigo
-
Publication number: 20160207966Abstract: A polypeptide with improved alkaline stability, which polypeptide comprises a mutant of a B or C domain of Staphylococcus Protein A, as specified by SEQ ID NO 1 or SEQ ID NO 2, or of Protein Z, as specified by SEQ ID NO 3, wherein at least the glutamine residue at position 15 has been mutated to an amino acid other than asparagine. The invention also discloses multimers of the polypeptide, as well as separation matrices comprising the multimers or polypeptides.Type: ApplicationFiled: July 10, 2014Publication date: July 21, 2016Inventors: Mats ANDER, Goran BAUREN, Tomas BJORKMAN, Gustav RODRIGO
-
Publication number: 20160159855Abstract: A polypeptide with improved alkaline stability, which polypeptide comprises a mutant of a B or C domain of Staphylococcus Protein A, as specified by SEQ ID NO 1 or SEQ ID NO 2, or of Protein Z, as specified by SEQ ID NO 3, wherein at least the glutamine residue at position 9 has been mutated to an amino acid other than asparagine. The invention also discloses multimers of said polypeptide, as well as separation matrices comprising the multimers or polypeptides.Type: ApplicationFiled: July 8, 2014Publication date: June 9, 2016Inventors: Gustav Rodrigo, Mats Ander, Tomas BJORKMAN, Goran Bauren
-
Publication number: 20160159857Abstract: The invention discloses a polypeptide with improved alkaline stability, which polypeptide comprises a mutant of a B or C domain of Staphylococcus Protein A (SpA), as specified by SEQ ID NO 1 or SEQ ID NO 2, or of Protein Z, as specified by SEQ ID NO 3, comprising at least the mutation wherein the glutamine residue at position 9 has been mutated to a tryptophan, leucine, glutamic acid, valine or lysine. The invention also discloses multimers of the polypeptide, as well as separation matrices comprising the multimers or polypeptides.Type: ApplicationFiled: December 7, 2015Publication date: June 9, 2016Applicant: GE Healthcare Bio-Sciences ABInventors: Gustav Rodrigo, Mats Ander, Göran Baurén, Tomas Björkman
-
Publication number: 20150080554Abstract: The invention discloses an immunoglobulin-binding protein comprising one or more mutated immunoglobulin-binding domains (monomers) of staphylococcal Protein A (E, D, A, B, C) or protein Z or a functional variant thereof, wherein in at least one of the one or more mutated monomers, the asparagine or histidine at the position corresponding to H18 of the B domain of Protein A or of Protein Z has been deleted or substituted with a first amino acid residue which is not proline or asparagine and wherein, if the amino acid residue at position 57 is proline and the amino acid residue at position 28 is asparagine, then the amino acid residue at the position corresponding to H18 of the B domain of protein A or of protein Z is not serine, threonine or lysine.Type: ApplicationFiled: March 26, 2013Publication date: March 19, 2015Applicant: GE HEALTHCARE BIO-SCIENCES ABInventors: Mats Ander, Goran Bauren, Tomas Bjorkman, Per-Mikael Aberg, Gustav Rodrigo
-
Publication number: 20030175908Abstract: Methods of manipulation of nucleic acid, in particular amplification by means of the polymerase chain reaction (PCR), including use of oligonucleotides and combinations and kits comprising such oligonucleotides, also methods comprising use of nested PCR, allowing for improved results in methods wherein large numbers of nucleic acid fragments are manipulated by means of PCR and electrophoresis. Oligonucleotides are provided for use a size standards in electrophoresis, and internal controls allowing for calculation of relative amounts of material present. Improved results can be achieved in methods of profiling mRNA transcribed in a system under investigation.Type: ApplicationFiled: January 28, 2003Publication date: September 18, 2003Inventors: Sten Linnarsson, Patrik Ernfors, Goran Bauren, Ats Metsis, Arno Pihlak, Andreas Montelius
-
Publication number: 20030165952Abstract: A method for identifying mRNA molecules present in a sample, and also for quantifying the expression levels of the mRNA molecules. A profile of gene identities and/or expression levels is produced by generating two independent patterns characteristic of the population of mRNA molecules expressed in the sample and analysing these patterns using a combinatorial algorithm. Gene expression by different cell types or of the same cell types under different conditions may be compared. In this way, genes may be identified which play a role in determining various cellular processes and states, including susceptibility to external factors, development, and disease.Type: ApplicationFiled: April 9, 2003Publication date: September 4, 2003Inventors: Sten Linnarsson, Patrik Ernfors, Goran Bauren